Modified VWF Molecule Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bleeding disorders such as hemophilia A and von Willebrand disease require frequent administration of Factor VIII and von Willebrand factor (VWF) due to their short half-lives, which is cumbersome and poses infection risks, especially when administered at home.
Innovation Solution
Modification of VWF molecules by deleting or substituting amino acids at specific O-linked glycosylation sites, particularly at position 2298, to reduce interaction with CLEC10A receptor, thereby prolonging their half-life and enhancing their binding affinity with Factor VIII, allowing for less frequent administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FVIII is administered frequently (3 times per week), then the coagulation function is maintained, but the treatment burden and infection risk increase
Solution Approach 1:
The patent modifies the amino acid sequence of VWF by deleting or substituting specific residues (e.g., position 2298 in the C1 domain) to alter its interaction with CLEC10A receptors. This parameter change in the molecular structure extends the plasma half-life of FVIII from 12-14 hours to potentially 48 hours or more, enabling less frequent administration while maintaining therapeutic efficacy
Solution Approach 2:
The invention extracts and removes the specific amino acid sequence elements responsible for rapid clearance by CLEC10A (particularly the O-glycosylation site at position 2298). By taking out these harmful interaction sites while preserving the overall VWF structure and FVIII binding capability, the modified VWF achieves extended circulation time
2Duration of action of moving object
If FVIII half-life is extended by modifying VWF structure, then administration frequency is reduced, but the complexity of manufacturing increases
Solution Approach 1:
The patent employs site-specific amino acid deletions or substitutions in the VWF sequence (e.g., deleting Thr-2298 or substituting with non-glycosylatable residues). These targeted parameter changes in the primary structure are sufficient to prevent CLEC10A recognition and extend half-life, while maintaining compatibility with standard recombinant expression systems
Solution Approach 2:
Rather than globally modifying the entire VWF molecule or FVIII complex, the invention applies localized changes only at specific critical residues (such as position 2298 in the C1 domain). This local quality modification approach minimizes manufacturing complexity while achieving the desired pharmacokinetic improvement
3Reliability
If VWF binds strongly to CLEC10A, then clearance is rapid, but half-life is short requiring frequent dosing
Solution Approach 1:
The patent identifies the harmful interaction between native VWF and CLEC10A that causes rapid clearance. By modifying VWF to eliminate this interaction (through amino acid deletion/substitution at position 2298), the invention converts the previously harmful clearance pathway into a beneficial extended circulation time, allowing the VWF-FVIII complex to remain in plasma longer without triggering rapid removal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified VWF molecules increase the half-life of Factor VIII, reducing the frequency of administration and minimizing infection risks, thereby improving treatment efficacy and patient convenience.
Implementation Method 1
VWF serves as a carrier and stabilizing protein for procoagulant FVIII
Implementation Method 2
VWF monomers strongly bind to calcium-type lectin domain family 10 member A (CLEC10A), a receptor protein present on macrophages
Data Source
AI summary
The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.